# Rigontec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rigontec

- Industry: Pharmaceuticals
- Headquarters: Munich, Germany
- Website: www.rigontec.de
- Total disclosed funding: $34M
- Latest round: Series A (Sep 6, 2016)
- Investors on record: 7

## About

Established in 2014 and based in Bonn, Germany, Rigontec GmbH operates as a biopharmaceutical company that develops 3pRNA-based immunotherapeutics for the treatment of cancer and viral diseases.

## Funding rounds

- Series A, Sep 6, 2016, $17M — Wellington Partners, Forbion, Heartcore Capital, NRW Bank, Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Sunstone Life Science Ventures
- Series A, Mar 24, 2015, $5.2M — Forbion, Sunstone Life Science Ventures
- Series A, Oct 14, 2014, $12M — Wellington Partners, NRW Bank, Boehringer Ingelheim Venture, High-Tech Gruenderfonds

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A
- NRW Bank — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Sunstone Life Science Ventures (https://capitalatlas.ai/funds/sunstone-life-science-ventures) — Series A
- Heartcore Capital (https://capitalatlas.ai/funds/heartcore-capital) — Series A